Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 13/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | PKM | P14618 | 7/20 | 0.57 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 11/20 | 0.56 |
| ▸ | POLB | P06746 | 7/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.51 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.51 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190455 | 0.85 | MAPT (0.66) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL8190456 | 0.85 | MAPT (0.66) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL8191326 | 0.85 | MAPT (0.66) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL17833968 | 0.81 | KMT2A (0.65) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL12177202 | 0.80 | ALDH1A1 (0.60) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL2302382 | 0.79 | KMT2A (0.62) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL2302380 | 0.79 | KMT2A (0.62) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL12177733 | 0.79 | RAB9A (0.77) | MAPTALDH1A1KMT2AMEN1POLB | |
| SCHEMBL12177529 | 0.76 | ALDH1A1 (0.59) | MAPTALDH1A1KMT2AKDM4EPKM | |
| SCHEMBL12177526 | 0.74 | MAP3K5 (0.60) | MAPTALDH1A1KMT2AKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3243821-B1 | PHARMACEUTICAL FORMULATIONS FOR REGULATING INTEGRIN CD11B/CD18 | GB006 INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10239871-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328105-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2016-05-03 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023876-B2 | Compounds and methods for regulating integrins | ADHAERE PHARMACEUTICALS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ATEGRIN, INC. | 2015-04-16 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ATEGRIN, INC. | 2012-01-12 | — | — | US | disclosed |
| WO-2012005800-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRIN CD11B/CD18 | ADHAERE PHARAMACEUTICALS, INC. (US) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10239871-B2 | Compounds and methods for regulating integrins | ITGA2, ITGB2, ITGA2B | MAPT 4654/4885ALDH1A1 1927/4885KMT2A 2195/4885 |
| US-20120010255-A1 | Compounds and Methods for Regulating Integrins | ITGB8, ITGB3, ITGAM | MAPT 4318/4885ALDH1A1 473/4885KMT2A 2448/4885 |
| US-20150105435-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | MAPT 4654/4885ALDH1A1 1927/4885KMT2A 2195/4885 |
| US-20160151336-A1 | COMPOUNDS AND METHODS FOR REGULATING INTEGRINS | ITGA2, ITGB2, ITGA2B | MAPT 4654/4885ALDH1A1 1927/4885KMT2A 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.